[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
We report our experience with concurrent chemoradiation for recurrent gastric cancers resistant to TS-1. From April 2000 to March 2003, we treated 10 consecutive patients with radiation and the concurrent single chemotherapy agent of TS-1 or CPT-11. Of the 10 patients, 3 (30%) had a complete response, 4 (40%) a partial response, and 3 (30%) stable disease, yielding an overall response rate of 70% (7/10). Three patients are alive and cancer-free, 5 patients died with cancers, and 2 patients are living with cancers as outpatients. The clinical benefit response was 90% (9/10). No patient has had either acute or late complication. Concurrent chemoradiation is feasible and seems to offer good results for recurrent gastric cancers resistant to TS-1.
Akagi
Yukio
Y
Dept. of Radiology, Hiroshima Asa City Hospital.
Hashimoto
Yasutoshi
Y
Murakami
Yuji
Y
Ito
Katsuhide
K
D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010094:Oxonic Acid; D011725:Pyridines; D011788:Quality of Life; D011879:Radiotherapy Dosage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D005641:Tegafur
D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin